1,029,860 Sanofi $SNY Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Sanofi (NASDAQ:SNY) by 9.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,597,228 shares of the company’s stock after selling 1,029,860 shares during the period. Fisher Asset Management LLC’s holdings in Sanofi were worth $395,694,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after buying an additional 940,342 shares during the period. Mondrian Investment Partners LTD lifted its stake in Sanofi by 2.3% during the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after acquiring an additional 129,575 shares during the period. Royal Bank of Canada lifted its stake in Sanofi by 17.5% during the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after acquiring an additional 470,882 shares during the period. Regal Partners Ltd boosted its holdings in shares of Sanofi by 33.2% in the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock valued at $122,639,000 after acquiring an additional 633,782 shares during the last quarter. Finally, Equity Investment Corp boosted its holdings in shares of Sanofi by 1.3% in the 3rd quarter. Equity Investment Corp now owns 2,636,859 shares of the company’s stock valued at $108,718,000 after acquiring an additional 34,888 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research reports. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. DZ Bank restated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 2nd. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Sanofi has a consensus rating of “Hold” and an average target price of $53.00.

Sanofi Trading Up 0.1%

Shares of NASDAQ:SNY opened at $48.46 on Friday. Sanofi has a 12-month low of $39.07 and a 12-month high of $52.68. The company has a market capitalization of $117.49 billion, a PE ratio of 23.99, a PEG ratio of 1.33 and a beta of 0.31. The business has a 50 day moving average of $42.60 and a two-hundred day moving average of $44.37. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48. The business had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The business’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 EPS. As a group, analysts forecast that Sanofi will post 5.07 EPS for the current year.

Sanofi Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.